Gene mutations in hepatocellular adenomas

Histopathology

Volumn 66, Issue 7, 2015, Pages 910-921

  Raft, Marie B ^a   Jørgensen, Ernö N ^a   Vainer, Ben ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adenoma; Diagnosis, differential; Focal nodular hyperplasia; Hepatocellular; Hepatocellular carcinoma; Liver; Liver neoplasms; Mutation

Indexed keywords

BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; JANUS KINASE; STAT3 PROTEIN; TUMOR MARKER;

FATTY LIVER; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER ADENOMA; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; REVIEW; SIGNAL TRANSDUCTION; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; GENETICS; GENOTYPE; LIVER TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE; PROGNOSIS;

ADENOMA, LIVER CELL; BIOMARKERS, TUMOR; GENOTYPE; HUMANS; INFLAMMATION; LIVER NEOPLASMS; MUTATION; PHENOTYPE; PROGNOSIS;

EID: 84929130831     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12539     Document Type: Review

References (34)

1. Mettlin C, Natarajan N. Studies on the role of oral contraceptive use in the etiology of benign and malignant liver tumors. J. Surg. Oncol. 1981; 18; 73-85.
2. van Aalten SM, Witjes CD, de Man RA, Ijzermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma? Liver Int. 2012; 32; 28-37.
3. Bioulac-Sage P, Sempoux C, Possenti L et al. Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int. J. Hepatol. 2013; 2013; 253-261.
4. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013; 144; 888-902.
5. Bioulac-Sage P, Laumonier H, Couchy G et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50; 481-489.
6. Bioulac-Sage P, Cubel G, Taouji S et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am. J. Surg. Pathol. 2012; 36; 1691-1699.
7. Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin. Liver Dis. 2011; 31; 91-103.
8. Bluteau O, Jeannot E, Bioulac-Sage P et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 2002; 32; 312-315.
9. Reznik Y, Dao T, Coutant R et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J. Clin. Endocrinol. Metab. 2004; 89; 1476-1480.
10. Pelletier L, Rebouissou S, Paris A et al. Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 2010; 51; 557-566.
11. Rebouissou S, Imbeaud S, Balabaud C et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J. Biol. Chem. 2007; 282; 14437-14446.
12. Rebouissou S, Amessou M, Couchy G et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457; 200-204.
13. Pilati C, Amessou M, Bihl MP et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 2011; 208; 1359-1366.
14. Nault JC, Fabre M, Couchy G et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J. Hepatol. 2012; 56; 184-191.
15. Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002; 36; 927-935.
16. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009; 17; 9-26.
17. Zucman-Rossi J, Jeannot E, Nhieu JT et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43; 515-524.
18. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig. Surg. 2010; 27; 39-45.
19. Bioulac-Sage P, Taouji S, Le BB, Possenti L, Balabaud C. Value and limits of routine histology alone or combined with glutamine synthetase immunostaining in the diagnosis of hepatocellular adenoma subtypes on surgical specimens. Int. J. Hepatol. 2013; 2013; 417323.
20. Sempoux C, Chang C, Gouw A et al. Benign hepatocellular nodules: what have we learned using the patho-molecular classification. Clin. Res. Hepatol. Gastroenterol. 2013; 37; 322-327.
21. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J. Hepatol. 2008; 48; 163-170.
22. Bioulac-Sage P, Laumonier H, Rullier A et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int. 2009; 29; 459-465.
23. Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46; 740-748.
24. Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv. Anat. Pathol. 2011; 18; 438-445.
25. Pilati C, Letouze E, Nault JC et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014; 25; 428-441.
26. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin. Arthritis Rheum. 1990; 20; 129-147.
27. Joseph NM, Ferrell LD, Jain D et al. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod. Pathol. 2014; 27; 62-72.
28. Mathieu D, Kobeiter H, Maison P et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000; 118; 560-564.
29. Bioulac-Sage P, Rebouissou S, Sa CA et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128; 1211-1218.
30. Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl. Immunohistochem. Mol. Morphol. 2013; 21; 170-176.
31. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with beta-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum. Pathol. 2013; 44; 750-758.
32. Kakar S, Chen X, Ho C et al. Chromosomal abnormalities determined by comparative genomic hybridization are helpful in the diagnosis of atypical hepatocellular neoplasms. Histopathology 2009; 55; 197-205.
33. Kakar S, Grenert JP, Paradis V, Pote N, Jakate S, Ferrell LD. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor. Mod. Pathol. 2013, Apr 18. doi: 10.1038/modpathol.2014.50. [Epub ahead of print].
34. Nault JC, Mallet M, Pilati C et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013; 4; 2218.